The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
The remains of Steven Cook, a British tourist who disappeared more than a decade ago while on holiday, have been found.
The company said it had "considered pricing changes very carefully" and "sought to minimise the impact on customers".
Chief Executive Ross McEwan told ITV News he was "pleased" with the bank's performance and would therefore accept his role-based allowance.